
Sign up to save your podcasts
Or


In his weekly clinical update Dr. Griffin discusses prevalence and clinical outcomes of respiratory syncytial virus versus influenza virus in adults hospitalized with acute respiratory Illness, reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients, assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US, information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 Infection in the context of currently circulating Omicron sublineages, association of culturable-virus detection and household transmission of SARS-CoV-2, effectiveness of bivalent boosters against severe Omicron infection, Covid vaccines and playing the long game, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, and severe fatigue and persistent symptoms at three months following SARS-CoV-2 Infections during the pre-Delta, Delta, and Omicron time periods.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]
By Vincent Racaniello4.7
209209 ratings
In his weekly clinical update Dr. Griffin discusses prevalence and clinical outcomes of respiratory syncytial virus versus influenza virus in adults hospitalized with acute respiratory Illness, reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients, assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US, information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 Infection in the context of currently circulating Omicron sublineages, association of culturable-virus detection and household transmission of SARS-CoV-2, effectiveness of bivalent boosters against severe Omicron infection, Covid vaccines and playing the long game, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, and severe fatigue and persistent symptoms at three months following SARS-CoV-2 Infections during the pre-Delta, Delta, and Omicron time periods.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

321 Listeners

2,053 Listeners

454 Listeners

504 Listeners

756 Listeners

528 Listeners

171 Listeners

818 Listeners

6,467 Listeners

3,374 Listeners

281 Listeners

518 Listeners

367 Listeners

631 Listeners

91 Listeners